NCT02040870 - LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib | Biotech Hunter

Enrollment

103

Participants

Timeline

Start Date

March 7, 2014

Primary Completion Date

July 27, 2017

Study Completion Date

July 27, 2017

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

LDK378

750 mg once daily

Trial Locations (15)

Novartis Investigative Site, Guangzhou

Novartis Investigative Site, Beijing

Novartis Investigative Site, Beijing

Novartis Investigative Site, Beijing

Novartis Investigative Site, Beijing

Novartis Investigative Site, Changchun

Novartis Investigative Site, Shanghai

Novartis Investigative Site, Shanghai

Novartis Investigative Site, Hangzhou

Novartis Investigative Site, Chongqing

Novartis Investigative Site, Chongqing

Novartis Investigative Site, Guangzhou

Novartis Investigative Site, Guang Dong Province

Novartis Investigative Site, Chengdu

Novartis Investigative Site, Xi’an